Literature DB >> 31411965

Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices.

Marie-Anne van Stam1, Neil K Aaronson2, J L H Ruud Bosch3, Jacobien M Kieffer2, Jochem R N van der Voort van Zyp4, Corinne N Tillier5, Simon Horenblas6, Henk G van der Poel7.   

Abstract

BACKGROUND: Well-documented reports of patients' experiences with different treatments are important for helping localised prostate cancer (LPC) patients choose among the available treatment options.
OBJECTIVE: To document differences in patient-reported outcomes (PROs) following radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), and active surveillance (AS), and to evaluate how these PROs and other factors are associated with treatment decision regret. DESIGN, SETTING, AND PARTICIPANTS: A prospective, observational, multicentre study of men diagnosed with LPC (stage cT1-2) during 2014-2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients completed validated PRO measures (Quality of Life Questionnaire Core 30 [QLQ-C30], Quality of Life Questionnaire prostate cancer-specific module [QLQ-PR25], Decision Regret Scale, and the Memorial Anxiety Scale for Prostate Cancer) before treatment and at 3, 6, and 12mo after treatment. Mixed-effect models were used to describe different PRO patterns. RESULTS AND LIMITATIONS: The analytic cohort included 434 men (AS=32%; RP=45%; EBRT=12%; BT=10%). Follow-up response rates were above 90%. At 1-yr follow-up, (1) men who had received RP reported significantly (p<0.01) more urinary incontinence, sexual dysfunction, hormonal/masculinity-related symptoms, and less emotional distress; (2) those having received EBRT reported more sexual dysfunction, hormonal/masculinity-related symptoms, and physical distress; and (3) those having received BT reported more urinary obstruction and irritation symptoms, compared with patients under AS. Irrespective of the treatment modality, 23% of the patients reported clinically relevant treatment regret (99% confidence interval, 17-28%). Multivariate correlates of decision regret were hormonal/masculinity-related symptoms, educational level, and positive surgical margins.
CONCLUSIONS: Post-treatment physical and psychosocial functioning was significantly associated with specific treatment modalities and pretreatment functioning. Regret was relatively frequently reported by patients who experienced unwanted physical, psychosocial, and oncological outcomes. Greater efforts should be made to understand whether carefully educating patients about the possible consequences and effectiveness of treatments may help limit the feeling of treatment regret. PATIENT
SUMMARY: In men with localised prostate cancer, regret about the treatment choice was more common among those who experienced more treatment-related symptoms during the year after treatment.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Conservative treatment; Patient-reported outcome measures; Prostatectomy; Prostatic neoplasms; Quality of life; Radiotherapy; Regret

Mesh:

Year:  2018        PMID: 31411965     DOI: 10.1016/j.euo.2018.12.004

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  13 in total

Review 1.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 2.  Implementation of patient-reported outcome measures into health care for men with localized prostate cancer.

Authors:  Udit Singhal; Ted A Skolarus; John L Gore; Matthew G Parry; Ronald C Chen; Julie Nossiter; Alan Paniagua-Cruz; Arvin K George; Paul Cathcart; Jan van der Meulen; Daniela A Wittmann
Journal:  Nat Rev Urol       Date:  2022-03-08       Impact factor: 16.430

Review 3.  Robot-Assisted Radical Prostatectomy Maneuvers to Attenuate Erectile Dysfunction: Technical Description and Video Compilation.

Authors:  Spyridon P Basourakos; Keith Kowalczyk; Marcio Covas Moschovas; Vanessa Dudley; Andrew J Hung; Jonathan E Shoag; Vipul Patel; Jim C Hu
Journal:  J Endourol       Date:  2021-11       Impact factor: 2.942

4.  Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial.

Authors:  Donna L Berry; Fangxin Hong; Traci M Blonquist; Barbara Halpenny; Niya Xiong; Christopher P Filson; Viraj A Master; Martin G Sanda; Peter Chang; Gary W Chien; Randy A Jones; Tracey L Krupski; Seth Wolpin; Leslie Wilson; Julia H Hayes; Quoc-Dien Trinh; Mitchell Sokoloff
Journal:  Urol Oncol       Date:  2021-01-19       Impact factor: 2.954

5.  Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors.

Authors:  Barbara M Wollersheim; Kristel M van Asselt; Henk G van der Poel; Henk C P M van Weert; Michael Hauptmann; Valesca P Retèl; Neil K Aaronson; Lonneke V van de Poll-Franse; Annelies H Boekhout
Journal:  BMC Cancer       Date:  2020-07-08       Impact factor: 4.430

6.  Radical prostatectomy versus brachytherapy for clinically localized prostate cancer on oncological and functional outcomes: a meta-analysis.

Authors:  Pu Zhang; Bei Qian; Jiawei Shi; Yajun Xiao
Journal:  Transl Androl Urol       Date:  2020-04

7.  Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer.

Authors:  Roman O Kowalchuk; David Hillman; Thomas B Daniels; Carlos E Vargas; Jean-Claude M Rwigema; William W Wong; Bradley J Stish; Amylou C Dueck; Richard Choo
Journal:  Clin Transl Radiat Oncol       Date:  2021-09-15

8.  Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer.

Authors:  Niklas Westhoff; Ramona Ernst; Karl Friedrich Kowalewski; Laura Schmidt; Thomas Stefan Worst; Maurice Stephan Michel; Jost von Hardenberg
Journal:  World J Urol       Date:  2020-06-12       Impact factor: 4.226

9.  1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.

Authors:  Filippo Alongi; Michele Rigo; Vanessa Figlia; Francesco Cuccia; Niccolò Giaj-Levra; Luca Nicosia; Francesco Ricchetti; Gianluisa Sicignano; Antonio De Simone; Stefania Naccarato; Ruggero Ruggieri; Rosario Mazzola
Journal:  Radiat Oncol       Date:  2020-03-23       Impact factor: 3.481

Review 10.  Measuring Quality of Life Following Robot-Assisted Radical Prostatectomy.

Authors:  Graham R Hale; Mohammed Shahait; David I Lee; Daniel J Lee; Ryan W Dobbs
Journal:  Patient Prefer Adherence       Date:  2021-06-23       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.